文献速递类风湿关节炎

皮下与静脉托珠单抗治疗类风湿关节炎的真实世界疗效比较:泛欧注册研究

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries.
PubMed 文献 · RMD Open · 2018-11-05

该研究基于8个欧洲注册库的3448例类风湿关节炎患者,比较皮下与静脉托珠单抗的真实世界疗效。校正混杂后两组停药风险相似(HR 0.93,95%CI 0.80–1.09),1年CDAI缓解率亦相似,但静脉组CDAI低疾病活动度比例较低。结论认为皮下托珠单抗是静脉给药的有效替代,考虑到静脉给药成本,应优先选择皮下剂型。

要点

  • 校正后皮下与静脉托珠单抗的停药风险相似(HR 0.93,95%CI 0.80–1.09)。
  • 1年CDAI缓解率两组相似,静脉组10.4% vs 皮下组12.8%。
  • 静脉组1年CDAI低疾病活动度比例低于皮下组(41.0% vs 49.1%)。

核心结论

  • 皮下托珠单抗在药物留存和疗效上与静脉托珠单抗相似,是类风湿关节炎的合适替代方案。
  • 考虑静脉给药的成本,条件允许时应优先选择皮下托珠单抗。

研究设计与样本

  • 基于8个欧洲注册库的类风湿关节炎患者真实世界比较研究,共纳入3448例,其中静脉组2414例、皮下组1034例。
  • 采用未校正Kaplan-Meier法和校正基线患者、疾病及治疗特征的Cox模型比较药物留存,并按开始治疗年份和注册国家分层。
  • 采用匹配样本比较1年CDAI缓解和低疾病活动度比例,并用LUNDEX校正失访。

主要发现

  • 粗中位留存时间静脉组为3.52年(95%CI 3.22–3.85),皮下组为2.12年(95%CI 1.88–2.38)。
  • 校正分析中皮下与静脉组停药风险相似(HR 0.93,95%CI 0.80–1.09)。
  • 1年平均校正CDAI变化两组相似(-6.08)。
  • 匹配后每组560例,1年CDAI缓解率静脉组10.4% vs 皮下组12.8%(差异2.4%,bootstrap 95%CI -2.1%–7.6%)。
  • 1年CDAI低疾病活动度静脉组41.0% vs 皮下组49.1%(差异8.0%,bootstrap 95%CI 2.4%–12.4%)。

关键数值与推荐

  • 停药风险HR 0.93(95%CI 0.80–1.09),皮下组 vs 静脉组。
  • 1年CDAI缓解率差异2.4%(bootstrap 95%CI -2.1%–7.6%),静脉组10.4% vs 皮下组12.8%。
  • 1年CDAI低疾病活动度差异8.0%(bootstrap 95%CI 2.4%–12.4%),静脉组41.0% vs 皮下组49.1%。

临床怎么用

  • 皮下托珠单抗可作为静脉托珠单抗的替代给药方式用于类风湿关节炎。
  • 在条件允许时,考虑静脉给药成本,可优先选用皮下托珠单抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the real-word effectiveness of subcutaneous tocilizumab (TCZ-SC) and intravenous tocilizumab (TCZ-IV) in rheumatoid arthritis (RA). METHODS: Patients with RA with TCZ from eight European registries were included. Drug retention was compared using unadjusted Kaplan-Meier and Cox models adjusted for baseline patient, disease and treatment characteristics, using a strata term for year of treatment initiation and country of registry. The proportions of patients achieving Clinical Disease Activity Index (CDAI) remission and low disease activity (LDA) at 1 year were compared using samples matched on the same covariates and corrected for attrition using LUNDEX. RESULTS: 3448 patients were retrieved, 2414 with TCZ-IV and 1034 with TCZ-SC. Crude median retention was 3.52 years (95% CI 3.22 to 3.85) for TCZ-IV and 2.12 years for TCZ-SC (95% CI 1.88 to 2.38). In a country-stratified and year of treatment initiation-stratified, covariate-adjusted analysis, hazards of discontinuation were similar between TCZ-SC and TCZ-IV treated patients (HR 0.93, 95% CI 0.80 to 1.09). The average adjusted CDAI change at 1 year was similar in both groups (-6.08). After matching, with 560 patients in each group, CDAI remission corrected for attrition at 1 year was also similar between TCZ-SC and TCZ-IV (10.4% in TCZ-IV vs 12.8% in TCZ-SC (difference: 2.4%, bootstrap 95% CI -2.1% to 7.6%)), but CDAI LDA was lower in TCZ-IV patients: 41.0% in TCZ-IV versus 49.1% in TCZ-SC (difference: 8.0 %; bootstrap 95% CI 2.4% to 12.4%). CONCLUSION: With similar retention and effectiveness, TCZ-SC is an adequate alternative to TCZ-IV for RA. When possible, considering the costs of the TCZ-IV route, TCZ-SC should be the preferred mode of administration.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Lauper K, Mongin D, Iannone F, et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open. 2018. PMID: 30488002. doi:10.1136/rmdopen-2018-000809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。